{"id":"https://openalex.org/W4362540951","doi":"https://doi.org/10.1158/1538-7445.am2023-6147","title":"Abstract 6147: MCL1 inhibitor PRT1419 demonstrates anti-tumor activity in PBRM1-altered clear cell renal cancer and synergizes with standard of care agents","display_name":"Abstract 6147: MCL1 inhibitor PRT1419 demonstrates anti-tumor activity in PBRM1-altered clear cell renal cancer and synergizes with standard of care agents","publication_year":2023,"publication_date":"2023-04-04","ids":{"openalex":"https://openalex.org/W4362540951","doi":"https://doi.org/10.1158/1538-7445.am2023-6147"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2023-6147","doi":"https://doi.org/10.1158/1538-7445.am2023-6147","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2023-6147","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075101326","display_name":"Norman Fultang","orcid":"https://orcid.org/0000-0002-8115-7231","observed_orcids":["https://orcid.org/0000-0002-8115-7231"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Norman Fultang","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091724844","display_name":"Brian Vidal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Vidal","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085522301","display_name":"Ashley M. Schwab","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashley M. Schwab","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069730078","display_name":"Alexander Grego","orcid":"https://orcid.org/0009-0000-8724-7003","observed_orcids":["https://orcid.org/0009-0000-8724-7003"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexander Grego","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103115213","display_name":"Diane Heiser","orcid":"https://orcid.org/0009-0008-1757-914X","observed_orcids":["https://orcid.org/0009-0008-1757-914X","https://orcid.org/0000-0003-1239-8936"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diane Heiser","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046355139","display_name":"Kris Vaddi","orcid":"https://orcid.org/0009-0009-8581-6511","observed_orcids":["https://orcid.org/0009-0009-8581-6511"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kris Vaddi","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060435781","display_name":"Neha Bhagwat","orcid":"https://orcid.org/0009-0002-5766-0272","observed_orcids":["https://orcid.org/0009-0002-5766-0272"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neha Bhagwat","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018193992","display_name":"Peggy Scherle","orcid":"https://orcid.org/0000-0003-0783-6815","observed_orcids":["https://orcid.org/0000-0003-0783-6815"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peggy Scherle","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405265449"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"83","issue":"7_Supplement","first_page":"6147","last_page":"6147"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.7749000191688538,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.7749000191688538,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.1088000014424324,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.07159999758005142,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mcl-1-inhibitors","display_name":"Mcl-1 inhibitors","score":0.9430000185966492},{"id":"https://openalex.org/keywords/clear-cell-renal-cell-carcinoma","display_name":"clear cell renal cell carcinoma","score":0.8740000128746033},{"id":"https://openalex.org/keywords/pbrm1","display_name":"PBRM1","score":0.9309999942779541},{"id":"https://openalex.org/keywords/baf180","display_name":"BAF180","score":0.8379999995231628},{"id":"https://openalex.org/keywords/swi-snf-complex","display_name":"SWI/SNF complex","score":0.8500000238418579},{"id":"https://openalex.org/keywords/bcl-2-family-proteins","display_name":"Bcl-2 family proteins","score":0.7850000262260437},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.7590000033378601},{"id":"https://openalex.org/keywords/gene-essentiality","display_name":"gene essentiality","score":0.6779999732971191},{"id":"https://openalex.org/keywords/crispr-cas9-screening","display_name":"CRISPR-Cas9 screen","score":0.7770000100135803},{"id":"https://openalex.org/keywords/sunitinib","display_name":"sunitinib","score":0.8080000281333923},{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":0.9950000047683716},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.7289999723434448},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7910000085830688},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.4399999976158142},{"id":"https://openalex.org/keywords/rna-interference","display_name":"RNA interference","score":0.31200000643730164}],"concepts":[{"id":"https://openalex.org/C2779176958","wikidata":"https://www.wikidata.org/wiki/Q18028939","display_name":"MCL1","level":4,"score":0.8410714268684387},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6947306394577026},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5817047953605652},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.43728017807006836},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4032191336154938},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1935632824897766},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.17211338877677917},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.16796305775642395},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09065619111061096}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2023-6147","doi":"https://doi.org/10.1158/1538-7445.am2023-6147","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2023-6147","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4391482281","https://openalex.org/W3178391310","https://openalex.org/W4282982900","https://openalex.org/W6977802990","https://openalex.org/W2341816553","https://openalex.org/W2886404662","https://openalex.org/W3190184690","https://openalex.org/W4281606536","https://openalex.org/W2307624263","https://openalex.org/W4366465782"],"abstract_inverted_index":{"Abstract":[0],"Induced":[1],"myeloid":[2],"leukemia":[3],"cell":[4,32,119,128,135,139,264,387],"differentiation":[5],"protein":[6],"(MCL1)":[7],"is":[8,78,159,169,336],"a":[9,22,58,110,149,160,179,277],"member":[10],"of":[11,17,36,72,163,188,206,213,220,228,238,256,300,351,394,400],"the":[12,297,349,354,401],"B-cell":[13],"lymphoma-2":[14],"(BCL2)":[15],"family":[16],"apoptosis":[18,221],"regulators,":[19],"which":[20],"plays":[21],"critical":[23],"role":[24],"in":[25,38,68,82,87,144,172,184,199,224,233,242,306,312,322,326,343,384],"maintaining":[26],"cellular":[27],"homeostasis":[28],"and":[29,47,51,74,93,282,320,345,390,413],"promoting":[30],"cancer":[31,118,137,389],"survival.":[33],"Increased":[34,269],"expression":[35,255],"MCL1":[37,62,106,207,267,270,293,341,378],"various":[39,69,173,225,327],"cancers":[40,175],"has":[41,178,272],"been":[42,274],"associated":[43,337],"with":[44,89,141,186,253,308,317,338,392],"poor":[45],"prognosis":[46],"resistance":[48,278],"to":[49,105,247,280,340],"chemotherapeutic":[50],"targeted":[52,286],"agents.":[53,396],"We":[54,131,194],"previously":[55,196,273],"described":[56,197,275],"PRT1419,":[57],"novel,":[59],"potent,":[60],"selective":[61],"inhibitor":[63,208,379],"that":[64,101,133],"demonstrates":[65,381],"anti-tumor":[66,298,382],"efficacy":[67],"preclinical":[70,226],"models":[71,227],"solid":[73,95],"hematologic":[75,91],"malignancies.":[76],"PRT1419":[77,223,305,315,352,380],"currently":[79],"under":[80],"evaluation":[81,350],"Phase":[83],"I":[84],"clinical":[85],"trials":[86],"patients":[88],"relapsed/refractory":[90],"malignancies":[92],"advanced":[94],"tumors.":[96],"To":[97,290],"identify":[98],"novel":[99],"biomarkers":[100,205],"might":[102],"predict":[103],"sensitivity":[104,246,339],"inhibition,":[107],"we":[108,303],"conducted":[109],"gene":[111,121],"essentiality":[112],"analysis":[113],"using":[114],"publicly":[115],"available":[116],"human":[117,174],"line":[120],"dependency":[122,151],"data":[123],"generated":[124],"from":[125],"genome-wide":[126],"CRISPR/Cas9":[127],"viability":[129],"screens.":[130],"observed":[132,210],"clear":[134,386],"renal":[136,388],"(ccRCC)":[138],"lines":[140],"deleterious":[142],"alterations":[143,198],"PBRM1":[145,168,192,239,250,334],"(Polybromo":[146],"1)":[147],"displayed":[148],"strong":[150],"on":[152],"MCL1.":[153],"PBRM1,":[154],"also":[155],"known":[156],"as":[157,204,216,218,276],"BAF180,":[158],"chromatin-targeting":[161],"subunit":[162],"mammalian":[164,201],"pBAF":[165],"(SWI/SNF-B)":[166],"complexes.":[167],"frequently":[170],"altered":[171],"but":[176,231],"it":[177],"particularly":[180],"high":[181],"alteration":[182],"rate":[183],"ccRCC":[185,230,244,344,358],"~40%":[187],"tumors":[189],"harboring":[190],"damaging":[191],"alterations.":[193],"had":[195],"other":[200],"SWI/SNF":[202],"factors":[203],"sensitivity.We":[209],"potent":[211],"inhibition":[212,294,342],"tumor":[214,235,324],"growth":[215,325],"well":[217],"induction":[219],"by":[222],"PBRM1-mutant":[229],"not":[232],"PBRM1-WT":[234,243],"models.":[236,328],"Depletion":[237],"via":[240],"RNAi":[241],"induced":[245],"PRT1419.":[248],"Mechanistically,":[249],"depletion":[251],"coincided":[252],"increased":[254],"pro-apoptotic":[257],"factors,":[258],"priming":[259],"PBRM1-loss":[260,313],"cells":[261],"for":[262,288,348,353,356,404],"caspase-mediated":[263],"death":[265],"following":[266],"inhibition.":[268],"activity":[271,383],"mechanism":[279],"Sunitinib":[281,309,319],"Everolimus,":[283],"two":[284],"approved":[285],"agents":[287],"ccRCC.":[289,314],"investigate":[291],"if":[292],"could":[295],"potentiate":[296],"effects":[299],"these":[301,331],"agents,":[302],"evaluated":[304],"combination":[307],"or":[310],"Everolimus":[311,321],"synergized":[316],"both":[318],"inhibiting":[323],"Taken":[329],"together,":[330],"findings":[332],"suggest":[333],"loss":[335],"provide":[346],"rationale":[347],"treatment":[355],"PBRM1-deficient":[357],"Citation":[359],"Format:":[360],"Norman":[361],"Fultang,":[362],"Brian":[363],"Vidal,":[364],"Ashley":[365],"M.":[366],"Schwab,":[367],"Alexander":[368],"Grego,":[369],"Diane":[370],"Heiser,":[371],"Kris":[372],"Vaddi,":[373],"Neha":[374],"Bhagwat,":[375],"Peggy":[376],"Scherle.":[377],"PBRM1-altered":[385],"synergizes":[391],"standard":[393],"care":[395],"[abstract].":[397],"In:":[398],"Proceedings":[399],"American":[402],"Association":[403],"Cancer":[405,424],"Research":[406],"Annual":[407],"Meeting":[408],"2023;":[409],"Part":[410],"1":[411],"(Regular":[412],"Invited":[414],"Abstracts);":[415],"2023":[416],"Apr":[417],"14-19;":[418],"Orlando,":[419],"FL.":[420],"Philadelphia":[421],"(PA):":[422],"AACR;":[423],"Res":[425],"2023;83(7_Suppl):Abstract":[426],"nr":[427],"6147.":[428]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2023-04-06T00:00:00"}